Skip to main content
SpringerLink
Log in

Exemestane: the dawn of a new era in breast cancer treatment

  • Letter to the Editor
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Coleman RE, Banks LM, Girgis SI et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES): a randomised controlled study. Lancet Oncol 8:119–127

    Article  PubMed  CAS  Google Scholar 

  • Coombes RC, Hall E, Snowdon CF et al (2004) The intergroup exemestane study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two or three years of tamoxifen-updated survival analysis. Breast Cancer Res Treat 88(Suppl 1):S7

    Google Scholar 

  • Jones SE, Cantrell J, Vukelja S et al (2007) Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a tamoxifen exemestane adjuvant multicenter trial substudy. J Clin Oncol 25:4765–4771

    Article  PubMed  CAS  Google Scholar 

  • Markopoulos C, Polychronis A, Zobolas V et al (2005) The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 3:61–66

    Article  Google Scholar 

  • Risebrough NA, Verma S, Trudeau M, Mittmann N (2007) Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer 110:499–508

    Article  PubMed  CAS  Google Scholar 

  • Rose C (2008) Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials. J Cancer Res Clin Oncol 134:7–17

    Article  PubMed  CAS  Google Scholar 

  • Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC (2007) Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health 10:367–376

    Article  PubMed  Google Scholar 

  • Traina TA, Poggesi I, Robson M et al (2007) Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat (in press)

Download references

Author information

Authors and Affiliations

  1. University of Illinois at Chicago, Chicago, IL, 60612, USA

    Shailendra Kapoor

Authors
  1. Shailendra Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shailendra Kapoor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kapoor, S. Exemestane: the dawn of a new era in breast cancer treatment. J Cancer Res Clin Oncol 134, 819–820 (2008). https://doi.org/10.1007/s00432-008-0363-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-008-0363-9

Keywords

Search

Navigation